Frank Rimerman Advisors LLC Acquires 181 Shares of Becton, Dickinson and Company (NYSE:BDX)

Frank Rimerman Advisors LLC boosted its holdings in Becton, Dickinson and Company (NYSE:BDX) by 7.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,550 shares of the medical instruments supplier’s stock after acquiring an additional 181 shares during the quarter. Frank Rimerman Advisors LLC’s holdings in Becton, Dickinson and Company were worth $579,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in BDX. Principal Financial Group Inc. raised its stake in Becton, Dickinson and Company by 1.5% during the 3rd quarter. Principal Financial Group Inc. now owns 1,179,715 shares of the medical instruments supplier’s stock valued at $284,429,000 after buying an additional 16,918 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in Becton, Dickinson and Company during the 3rd quarter valued at $458,000. CIBC Asset Management Inc raised its stake in Becton, Dickinson and Company by 5.2% during the 3rd quarter. CIBC Asset Management Inc now owns 56,923 shares of the medical instruments supplier’s stock valued at $13,717,000 after buying an additional 2,824 shares during the last quarter. Empowered Funds LLC raised its stake in Becton, Dickinson and Company by 9.2% during the 3rd quarter. Empowered Funds LLC now owns 5,867 shares of the medical instruments supplier’s stock valued at $1,415,000 after buying an additional 496 shares during the last quarter. Finally, Natixis Advisors LLC raised its stake in Becton, Dickinson and Company by 208.9% during the 3rd quarter. Natixis Advisors LLC now owns 236,682 shares of the medical instruments supplier’s stock valued at $57,064,000 after buying an additional 160,073 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 2,838 shares of the stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $223.33, for a total transaction of $633,810.54. Following the completion of the transaction, the executive vice president now owns 6,141 shares of the company’s stock, valued at $1,371,469.53. This represents a 31.61 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeffrey William Henderson acquired 1,500 shares of the company’s stock in a transaction on Monday, February 10th. The shares were bought at an average cost of $233.62 per share, with a total value of $350,430.00. Following the acquisition, the director now directly owns 8,015 shares in the company, valued at approximately $1,872,464.30. The trade was a 23.02 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders sold 7,363 shares of company stock valued at $1,676,105. Company insiders own 0.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on BDX shares. Piper Sandler boosted their target price on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, January 28th. Barclays boosted their target price on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Finally, StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, March 5th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, Becton, Dickinson and Company has an average rating of “Buy” and a consensus price target of $278.29.

Becton, Dickinson and Company Trading Up 1.6 %

NYSE:BDX opened at $226.43 on Monday. The firm has a market capitalization of $65.02 billion, a price-to-earnings ratio of 37.61, a price-to-earnings-growth ratio of 1.63 and a beta of 0.35. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63. The business has a fifty day moving average price of $232.78 and a 200-day moving average price of $232.29. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. Sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company declared that its board has approved a stock repurchase plan on Tuesday, January 28th that authorizes the company to buyback 10,000,000 shares. This buyback authorization authorizes the medical instruments supplier to reacquire shares of its stock through open market purchases. Shares buyback plans are generally a sign that the company’s leadership believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be issued a $1.04 dividend. This represents a $4.16 annualized dividend and a yield of 1.84%. The ex-dividend date is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is currently 69.10%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.